Immuron
Follow
Get notifications in MyBN when activity occurs.
Industry Lists
Public Companies - non WAImmuron Limited (IMC) is an oral immunotherapy research and development and product sales focused on bovine-colostrum enriched with antibodies of choice for the treatment and prevention of a range of infectious and immune modulated diseases.
Product sales comprise Travelan and Protectyn, used for the prevention of travellers' diarrhoea.
The group is involved in research & development and hyperimmune products (occur predominantly in Australia, the Unites States and Canada).
Lists and Charts
Share price
Closing price for the last 90 trading days
Powered by Morningstar ®
Total Shareholder Return as at 31/10/24
| Rank | Company | 1 yr | 5 yr |
|---|---|---|---|
| 766th | Immuron | 6% | -10% |
1740 WA (and selected non WA) listed companies ranked by
1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| th |  | Immuron | $8.3m |
1334 listed non wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Share Transactions
Total value as at the date of the transaction
Powered by Morningstar ®
Company Activity
| NEW ROLE: Jeannie Joughin, Non-Executive Director | 31 Jul 2024 |
| NEWS: Tagged in Macro share price surges on winds of change | 08 Mar 2024 |
| NEW ROLE: Flavio Palumbo, | 30 Oct 2023 |
| NEW ROLE: Paul Brennan, Non-Executive Director, Non-Executive Chairman | 13 Apr 2023 |
| NEW ROLE: Steven Lydeamore, Chief Executive | 03 Nov 2022 |
| NEW ROLE: Thomas Liquard, Former Chief Executive Officer | 24 Nov 2020 |
| NEW ROLE: Jerry Kanellos, Chief Operating Officer | 03 Nov 2020 |
| NEW ROLE: Roger Aston, Non-Executive Chair | 03 Nov 2020 |
| NEW ROLE: Daniel Pollock, Non-Executive Director | 03 Nov 2020 |
